See more : Medley, Inc. (4480.T) Income Statement Analysis – Financial Results
Complete financial analysis of Biodexa Pharmaceuticals Plc (BDRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biodexa Pharmaceuticals Plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Comet Holding AG (COTN.SW) Income Statement Analysis – Financial Results
- Publicis Groupe S.A. (PGPEF) Income Statement Analysis – Financial Results
- Microbix Biosystems Inc. (MBXBF) Income Statement Analysis – Financial Results
- Golden Agri-Resources Ltd (GARPF) Income Statement Analysis – Financial Results
- Lucapa Diamond Company Limited (LOM.AX) Income Statement Analysis – Financial Results
Biodexa Pharmaceuticals Plc (BDRX)
About Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 381.00K | 699.00K | 578.00K | 343.00K | 674.00K | 1.94M | 989.00K | 1.32M | 1.38M | 157.00K | 147.00K | 0.00 |
| Cost of Revenue | 4.07M | 5.11M | 4.65M | 6.07M | 7.84M | 9.36M | 8.33M | 7.73M | 70.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.69M | -4.41M | -4.08M | -5.73M | -7.17M | -7.42M | -7.34M | -6.41M | 1.31M | 157.00K | 147.00K | 0.00 |
| Gross Profit Ratio | -967.45% | -631.19% | -705.19% | -1,669.10% | -1,063.65% | -382.92% | -742.16% | -484.28% | 94.91% | 100.00% | 100.00% | 0.00% |
| Research & Development | 4.07M | 5.11M | 4.65M | 16.15M | 7.84M | 9.36M | 9.83M | 7.73M | 8.71M | 5.44M | 2.84M | 1.65M |
| General & Administrative | 4.34M | 4.54M | 2.95M | 4.96M | 3.84M | 4.39M | 4.27M | 3.25M | 2.08M | 4.23M | 1.81M | 2.36M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 6.00K | 323.00K | 0.00 | 170.00K | 0.00 | 605.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 4.34M | 4.54M | 2.95M | 4.96M | 4.16M | 4.39M | 4.44M | 3.25M | 2.69M | 4.23M | 1.81M | 2.36M |
| Other Expenses | -4.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.33M | 4.05M | 1.99M | 17.71M | 3.67M | 4.39M | 5.54M | 2.07M | 12.59M | 9.84M | 4.65M | 4.01M |
| Cost & Expenses | 8.40M | 9.16M | 6.64M | 23.78M | 11.51M | 13.75M | 13.87M | 9.80M | 12.66M | 9.84M | 4.65M | 4.01M |
| Interest Income | 83.00K | 24.00K | 44.00K | 33.00K | 89.00K | 585.00K | 94.00K | 91.00K | 48.00K | 153.00K | 384.00K | 557.00K |
| Interest Expense | 41.00K | 53.00K | 44.00K | 34.00K | 97.00K | 587.00K | 109.00K | 0.00 | 0.00 | 161.00K | 248.00K | 0.00 |
| Depreciation & Amortization | 283.00K | 343.00K | 403.00K | 1.22M | 1.29M | 1.11M | 1.17M | 4.35M | 736.00K | 321.00K | 246.00K | 194.00K |
| EBITDA | -7.16M | -7.40M | -5.66M | -22.22M | -9.54M | -10.70M | -10.61M | -5.30M | -10.49M | -9.36M | -4.25M | -3.81M |
| EBITDA Ratio | -1,879.53% | -1,252.50% | -1,173.88% | -2,790.67% | -1,533.53% | -552.32% | -1,072.70% | -400.76% | -680.44% | -4,709.55% | -2,893.20% | 0.00% |
| Operating Income | -8.01M | -8.93M | -7.00M | -10.67M | -11.32M | -11.82M | -11.78M | -9.65M | -10.09M | -7.72M | -4.50M | -4.01M |
| Operating Income Ratio | -2,103.41% | -1,277.83% | -1,210.73% | -3,111.08% | -1,679.23% | -609.65% | -1,190.70% | -729.55% | -733.96% | -4,914.01% | -3,060.54% | 0.00% |
| Total Other Income/Expenses | 529.00K | 444.00K | 892.00K | -430.00K | 395.00K | -585.00K | -1.19M | 1.26M | 1.69M | -153.00K | -384.00K | -557.00K |
| Income Before Tax | -7.49M | -8.49M | -6.11M | -23.47M | -10.92M | -12.40M | -12.97M | -8.39M | -11.23M | -9.84M | -4.88M | -4.57M |
| Income Before Tax Ratio | -1,964.57% | -1,214.31% | -1,056.40% | -6,842.57% | -1,620.62% | -639.83% | -1,311.43% | -634.01% | -816.87% | -6,267.52% | -3,321.77% | 0.00% |
| Income Tax Expense | -406.00K | 832.00K | 646.00K | 1.28M | 1.79M | 2.03M | 1.27M | 2.23M | 1.13M | 1.02M | 799.00K | 571.00K |
| Net Income | -7.08M | -7.66M | -5.46M | -22.19M | -9.14M | -10.37M | -11.71M | -6.16M | -10.10M | -8.82M | -4.08M | -3.99M |
| Net Income Ratio | -1,858.01% | -1,095.28% | -944.64% | -6,469.10% | -1,355.79% | -534.98% | -1,183.52% | -465.68% | -734.47% | -5,619.11% | -2,778.23% | 0.00% |
| EPS | -224.13 | -619.72 | -542.31 | -4.14K | -3.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -224.13 | -619.72 | -542.31 | -4.14K | -3.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 31.59K | 12.35K | 10.07K | 5.36K | 2.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 31.59K | 12.35K | 10.07K | 5.36K | 2.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)---- $BDRX #BDRX--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc (“Biodexa” or “the Company”) (NASDAQ: BDRX). Investors who purchased Biodexa securities are encouraged to obtain additional information and...
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
NEW YORK , Oct. 27, 2024 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Company") (NASDAQ: BDRX). Investors who purchased Biodexa securities are encouraged...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Company") (NASDAQ:BDRX). Investors who purchased Biodexa securities are encouraged...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ: BDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc (“Biodexa” or “the Company”) (NASDAQ: BDRX). Investors who purchased Biodexa securities are...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Biodexa Pharmaceuticals Plc ("Biodexa" or the "Company") (NASDAQ:BDRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
Biodexa Pharmaceuticals Plc INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Biodexa Pharmaceuticals Plc (BDRX)
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biodexa Pharmaceuticals Plc ("Biodexa Pharmaceuticals Plc") (NASDAQ:BDRX) concerning possible violations of federal securities laws. On October 4, 2024,...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Company") (NASDAQ:BDRX). Investors who purchased Biodexa securities are encouraged...
Source: https://incomestatements.info
Category: Stock Reports